Initiation and Adjusting Insulin Therapy, am I doing it right? DMT2

Michelle Mangual, MD

Diplomate of the American Board of Internal Medicine and Endocrinology, Diabetes and Metabolism

Diplomate of the American Board of Clinical Lipidology

November 14, 2021



Disclosures

No conflict of interest





Learning Objectives


- Identify patient and disease characteristics that help providers to establish appropriate individual glycemic targets.
- Discuss when to initiate insulin therapy based on current ADA Standards of Medical Care and AACE.
- Develop skills for calculating patients' initial insulin dosage and titrating insulin dosages based on individualized glycemic targets.
- Understand the concept of overbasalization and how to avoid it.
- Better understand how to advise patients on their options with regard to insulin therapy regimens.





Approach to Individualization of Glycemic Targets







Glycemic Recommendations for Many Non-Pregnant Adults With Diabetes

A1c	<7%*
Preprandial capillary plasma glucose	80-130 mg/dl*
Peak postprandial plasma glucose^	<180 mg/dl*

- *More stringent glycemic goals maybe appropriate for individual patients
- ^Postprandial glucose measurements should be made 1-2 hours after the beginning of the meal, generally peak levels in patients with diabetes.

AACE Glycemic Control Algorithm: When to Consider Insulin Therapy in Patients with T2DM

Strong recommendation to initiate therapy

Option for consideration as initial therapy

As treatment intensification

• A1C >9.0% and/or symptomatic hyperglycemia; with or without other antihyperglycemic agents

In combination with 1-2 other antihyperglycemic agents when A1C is ≥7.5%-9.0%

 Added to monotherapy or dual therapy when A1C goals are not met after 3 months




Choice of treatment depends on patient and medication

Therapeutic inertia in the treatment of hyperglycemia in patients with type 2 diabetes: A systematic review

First author, year	Country	Study period	N*	Index treatment	TI (addition to index treatment)	Patients who received TI, %†	HbA1c threshold‡	
Brown, 2004 ¹⁶ USA			Diet and exercise			>7.0%	1.9	
				Metformin		Not reported	>7.0%	3.5
				Sulfonylurea			>7.0%	2.8
	LICA	1994–2002	7,208	Metformin + sulfonylurea	Change of therapy		>7.0%	4.9
	USA	1994-2002	7,200	Diet and exercise	Griange of therapy	67	>8.0%	0.7
				Metformin		35	>8.0%	1.6
				Sulfonylurea		45	>8.0%	1.4
				Metformin + sulfonylurea]	19	>8.0%	2.5
				≥1 OAD		7 %	Variable	1.2
Halimi, 2012 ³⁴	France	2010	702	1 OAD	1 drug or dose incresses	7 %	≥6.5%	1.2
naiiiii, 2012	France	2010	102	2 OADs	1 drug or dose increase	7%	≥7.0%	1.2
				≥3 OADs		O§	≥8.0%	0.9
						65	≥7.0%	2.9#
					OAD	67	≥7.5%	1.9 [#]
						67	>8.0%	1.6*
						7	≥7.0%	>7.2*
				1 OAD	Insulin	8	≥7.5%	>7.1*
						9	≥8.0%	>6.9*.*
				•		72	≥7.0%	2.2*
					OAD or insulin	75	≥7.5%	1.5*
						76	≥8.0%	1.1*
				96		32	≥7.0%	>7.2*
Khunti, 2013 ³⁹	UK	2004–2011	62,896		OAD	32	≥7.5%	>7.2*
				_		30	≥8.0%	>6.9
						14	≥7.0%	>7.2*
				2 OADs	Insulin	17	≥7.5%	>7.2*
						20	≥8.0%	>6.9*
				•		45	≥7.0%	>7.2*
					OAD or insulin	49	≥7.5%	>7.2*
				_		50	≥8.0%	6.3 [#]
						18	≥7.0%	>7.1*/
				3 OADs	Insulin	21	≥7.5%	>6.1*.**
						22	≥8.0%	>6.0*.**
Zografou, 2014 ⁶⁹ UK		UK 2002–2011	2–2011 509	Not insulin			>7.0%	4.1***
	UK				Initiation of insulin	1001	>8.0%	2.1*.††
							>9.0%	0.8*.††
			09–2013 90,497	1 OAD	Initiation of insulin		>8.0%	0.4
Hugie 0040%	LICA	2000 2012		2 OADs 3 OADs		1001	>8.0%	0.9
Hugie, 2016 ³⁶	USA	2009-2013				1001	>8.0%	1.2
				>3 OADs	1		>8.0%	1.3

Khunti K, et al. Diabetes Obes Metab. 2018;20:427-437.

Is A1c above target despite dual/triple therapy?
What's next?



- When selecting GLP-1 RA, consider: patient preference, A1C lowering, weight-lowering effect, or frequency of injection. If CVD, consider GLP-1 RA with proven CVD benefit. Oral or injectable GLP-1 RA are appropriate.
- 3. For patients on GLP-1 RA and basel insulin combination, consider use of a fixed-ratio combination product (DegLira or iGlarLixt)
- Consider switching from evening NPH to a basel analog if the patient develops hypoglycemia and/or frequently forgets to administer NPH in the evening and would be better managed with an AM dose of a long-acting basel insulin.
- the state of the s

The Treat-to-Target Trial

Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

MATTHEW C. RIDDLE, MD¹
JULIO ROSENSTOCK, MD²
IOHN GERICH. MD³

ON BEHALF OF THE INSULIN GLARGINE 4002 STUDY INVESTIGATORS*


The first study to force-titrate insulin dosages to achieve a prespecified treatment goal; enabled comparison of safety endpoints to establish risk-benefit of a newer basal insulin





Matthew C. Riddle et al. Dia Care 2003;26:3080-3086



Effects on glycemic parameters of adding insulin to patients previously treated with 1-2 oral agents with A1c >7.5% (n=756)











Cumulative Number of Hypoglycemia Events: The Treat-to-Target Trial








Matthew C. Riddle et al. Dia Care 2003;26:3080-3086



Basal Insulin Added to Oral Agents Improves Glycemic Control


24-week noninferiority trial of 973 insulin-naive patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs



- Similar hypoglycemia rates (<30% symptomatic)
- Changes in body weight (kg):
 - Insulin glargine: 1.4
 - Insulin detemir: 0.6 (*P* < 0.001)
- Final insulin doses (units/day):
 - Insulin glargine: 43.5
 - Insulin detemir: 76.5 (P < 0.001)

More Similarities Than
Differences Testing Insulin
Glargine 300 Units/mL
Versus Insulin Degludec
100 Units/mL in InsulinNaive Type 2 Diabetes: The
Randomized Head-to-Head
BRIGHT Trial






Initiation of basal insulin





If A1c >8% consider starting dose 0.2-0.3 units/kg



Bedtime or morning longacting insulin or bedtime intermediate-acting insulin

Daily dose: 10 units or 0.1-0.2 units/Kg



American Diabetes Association Dia Care 2021;44:S111-S124. Garber A J, et al. Endocr Pract. 2020;26(1):107-139






Titration of Basal Insulin

START

Basal Insulin

Daily dose: 10 units or 0.1-0.2 units/kg



Check FPG daily with SMBG

- Patient self-titration is more effective
- Set FPG target that correlates to A1c target

ADJUST

Choose evidence-based titration algorithm (e.g., increase 2 units every 3 days) to reach FPG target without hypoglycemia



If signs/symptoms of hypoglycemia, address cause and reduce insulin dose by 10-20%



Continue regimen and check A1c every 3 months

American Diabetes Association Dia Care 2021;44:S111-S124. Inzucchi, SE, et al. Dia Care 2015;38:140-149





Assess Adequacy of Basal Insulin Dose

Overbasalization? Need to consider adjunctive therapies?

- Basal dose >0.5 IU/kg
- Elevated bedtimemorning
- Hypoglycemia
- High variability

Open Access Research


BMJ Open Diabetes Research & Care BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin

Ariel Zisman,¹ Francienid Morales,² John Stewart,³ Andreas Stuhr,⁴ Aleksandra Vlajnic,² Rong Zhou⁵

Assess Adequacy of Basal Insulin Dose

Date	Fasting	Bedtime		
Mon	100 mg/dl	180 mg/dl		
Tue	95 mg/dl	175mg/dl		
Wed	80 mg/dl	168 mg/dl		
Thu	110 mg/dl	200 mg/dl		
Fri	105 mg/dl	190 mg/dl		
Sat	99 mg/dl	170 mg/dl		











If above A1C target

Consider GLP-1 RA if not already in regimen

For addition of GLP-1 RA, consider lowering insulin dose dependent on current glycemic assessment and patient factors

Add prandial insulin⁶

Usually one dose with the largest meal or meal with greatest PPG excursion; prandial insulin can be dosed individually or mixed with NPH as appropriate

INITIATION:

- 4 IU a day or 10% of basal insulin dose
- If A1C <8% (64 mmol/mol) consider lowering the basal dose by 4 IU a day or 10% of basal dose

TITRATION:

- Increase dose by 1-2 IU or 10-15% twice weekly
- For hypoglycemia determine cause, if no clear reason lower corresponding dose by 10-20%

If on bedtime NPH, consider converting to twice-daily NPH regimen

Conversion based on individual needs and current glycemic control. The following is one possible approach:

INITIATION:

- Total dose = 80% of current bedtime NPH dose
- 2/3 given in the morning
- 1/3 given at bedtime

TITRATION:

Titrate based on individualized needs

If above A1C target

If above A1C target



American Diabetes Association Dia Care 2021;44:S111-S124.



When Basal Insulin Is Not Enough to Control Glycemia

 Patients whose glycemia remains uncontrolled while receiving basal insulin in combination with oral agents or GLP-1 RAs may require mealtime insulin to cover postprandial hyperglycemia.^{1,2}

Basal Plus Prandial

Prandial insulin added to 1,2, or 3 meals^{1,2}

Basal-Bolus

Prandial insulin added to every meal¹

Premixed

Combination short and intermediate acting insulin²



1. Garber A J, et al. Endocr Pract. 2020;26(1):107-139. 2. American Diabetes Association Dia Care 2021;44:S111-S124.





Consider GLP-1 RA if not already in regimen

For addition of GLP-1 RA, consider lowering insulin dose dependent on current glycemic assessment and patient factors

V

Add prandial insulin⁶

If above A1C target

Usually one dose with the largest meal or meal with greatest PPG excursion; prandial insulin can be dosed individually or mixed with NPH as appropriate

INITIATION:

..........

- 4 IU a day or 10% of basal insulin dose
- If A1C <8% (64 mmol/mol) consider lowering the basal dose by 4 IU a day or 10% of basal dose

TITRATION:

- Increase dose by 1-2 IU or 10-15% twice weekly
- For hypoglycemia determine cause, if no clear reason lower corresponding dose by 10-20%

If on bedtime NPH, consider converting to twice-daily NPH regimen

Conversion based on individual needs and current glycemic control. The following is one possible approach:

INITIATION:

- Total dose = 80% of current bedtime NPH dose
- = 2/3 given in the morning
- 1/3 given at bedtime


TITRATION:

Titrate based on individualized needs

If above A1C target

If above A1C target









	Brea	kfast	Lunch		Dinner		Bedtime
	Pre	Post	Pre	Post	Pre	Post	
Mon	130	160	146	200	180	200	190
Tue	110	140	150	220	190	210	200
Wed	105	145	143	199	178	220	180
Thu	125	158	138	198	170	190	174
Fri	113	161	130	190	168	185	185
Sat	108	149	147	207	191	210	192
Sun	129	165	138	198	178	187	210



BeAm = >60 mg/dl Reduced Basal Insulin by 4 U or 10% Add 4 U lispro before lunch





If above A1C target

Stepwise additional injections of prandial insulin

(i.e., two, then three additional injections)

Proceed to full basal-bolus regimen

(i.e., basal insulin and prandial insulin with each meal)

Consider self-mixed/split insulin regimen

Can adjust NPH and short/rapid-acting insulins separately

INITIATION:

- Total NPH dose = 80% of current NPH dose
- 2/3 given before breakfast
- 1/3 given before dinner
- Add 4 IU of short/rapid-acting insulin to each injection or 10% of reduced NPH dose

TITRATION:

 Titrate each component of the regimen based on individualized needs

Consider twice daily premix insulin regimen

INITIATION:

 Usually unit per unit at the same total insulin dose, but may require adjustment to individual needs

TITRATION:

 Titrate based on individualized needs



Using Premixed Insulin

Pros

- Only one co-pay
- Patient with a predictable schedule with regular meals and with a lower risk of hypoglycemia.
- Patients often need fewer shots (1-2 per day)
- Premixed R & N has the lowest cost.
- Premixed Humalog 50/50 for patients with high carbohydrate meals.

Cons

- Patients must eat regular meals or they will be at a greater risk for hypoglycemia.
- More nocturnal hypoglycemia
- Premixed Regular & NPH has a greater risk for hypoglycemia.
- There is an increased need for between meal snacks.







STARTING PREMIXED ANALOG INSULIN: WHEN TO TEST AND HOW TO ADJUST YOUR DOSE

(USING HUMALOG MIX 75/25%* OR NOVOLOG MIX 70/30%* | For Patients Who Are Not On Basal Insulin)

HOW TO START PREMIXED INSULIN

The first dose should be 10% of the patient's weight in pounds (i.e. 220 lbs = 22 units) taken once daily at the largest meal.

When Premixed Insulin Is Taken:	When To Test Blood Sugar:	If The Blood Sugar Results Are:	Then You Should:	
		Under 80	Subtract 2 Units Every 3-5 Days Until Blood Sugar is 80–130 Before Dinner	
At Breakfast	Before Dinner	80-130	Do Not Adjust	
		Over 130	Add 2 Units Every 3-5 Days Until Blood Sugar is 80–130 Before Dinner	
	Before Bed	80-130	Eat a Small Snack	
At Dinner		130-180	For Most People on Premixed Insulin, This is a Good Blood Sugar Goal to Have in Order to Avoid Hypoglycemia During the Night.	
	Before Breakfast 80–130 Before Breakf Before Breakfast 80–130 Do Not Adjust Dose Add 2 Units Every 3–5 Days Until	Dinner Under 8		Subtract 2 Units Every 3–5 Days Until Blood Sugar is 80–130 Before Breakfast
		Do Not Adjust Dose		
		Over 130	Add 2 Units Every 3–5 Days Until Blood Sugar is 80–130 Before Breakfast	

If blood sugar is under 70, drink 1/2 cup of juice or soda or eat something that contains sugar. You can also take glucose tablets to bring your blood sugar into normal range. Let your physician/care team know that you had low blood sugar.



















Considering oral therapy in combination with injectable therapies.



CONSIDERING ORAL THERAPY IN COMBINATION WITH INJECTABLE THERAPIES



METFORMIN



Continue treatment with metformin

SGLT2i



If on SGLT2i, continue treatment

Consider adding SGLT2i if

- Established CVD
- If HbA₁ above target or as weight reduction aid





Stop TZD when commencing insulin OR reduce dose



- DKA (euglycemic)
- Instruct on sick-day rules
- Do not down-titrate insulin over-aggressively

SULFONYLUREA



If on SU, stop or reduce dose by 50% when basal insulin initiated



Consider stopping SU if prandial insulin initiated or on a premix regimen

1. Contraindicated in some countries, consider lower dose. This combination has a high risk of fluid retention and weight gain

DPP-4i



Stop DPP-4i if **GLP-1 RA initiated**

Summary

- Type 2 diabetes is a progressive disease.
- Individualize your patients' glycemic target based on patient and disease characteristics.
- Provide patient-centered care and use shared decision-making to overcome barriers to injectable therapy.
- Consider GLP-1 RA as the first injectable before insulin.
- Initiate appropriate basal insulin based in the individual patient's hypoglycemia risk, weight concerns, and cost considerations.





Summary

- Basal insulin have a physiological maximum benefit around 0.8 units per Kg/day and prescribers should look beyond basal to prandial intervention.
- Intensification of therapy beyond basal can be accomplished through addition of GLP-1 RA or SGLT2 inhibitors.
- Addition of prandial insulin can be simplified by stepwise approach with close follow up and titration.
- Professional or intermittent CGM can illuminate need for intensification or directional changes in therapy.





"Insulin is not the enemy it is the misuse of insulin that is the enemy."

Richard Aguilar



